Radius targets quick ramp up for newly approved osteoporosis drug
BioPharma Dive: Biotech and Pharma news | April 30, 2017
Radius Health last week won U.S. approval of its osteoporosis drug Tymlos (abaloparatide), securing a green light from the Food and Drug Administration one month after the regulator had unexpectedly extended its review.